Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peter Glazer
Yale University, Department: Radiation Diagnostic/oncology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cybrexa Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Please see the attached document for the required information.
Novel DNA Repair Inhibitors for Cancer Therapy
Project Narrative. We seek to identify novel therapeutic agents that are selectively toxic to cancer cells and that specifically sensitize tumors to radiation or chemotherapy. We have discovered that a lupus-derived, cell-penetrating autoantibody (3E10) inhibits DNA repair and can increase the sensitivity of cancer cells to radiation and chemotherapy but is otherwise non-toxic to human cells. We have also developed novel peptide conjugates that selectively target tumors and spare normal tissues, and we will use these to deliver specific DNA repair inhibitors to cancer cells. We will investigate the mechanism of action of these agents and elucidate how they can best be used for cancer therapy.
Filed on October 26, 2017.
Tell us what you know about Peter Glazer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Peter Glazer filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Peter Glazer | Yale University | Conflict of Interest | Patrys, Limited | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | TruCode Gene Repair, Inc. | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | Patrys Limited | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | Tru Code (formerly PNA Innovations) | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | Cybrexa Therapeutics | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | TruCode | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | Tru Code (formerly PNA Innovations) | Value cannot be readily determined |
| Peter Glazer | Yale University | Conflict of Interest | TruCode | Value cannot be readily determined |
| Peter Glazer | Yale University | Conflict of Interest | TruCode Gene Repair, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.